Mirum Pharmaceuticals (MIRM)
(Real Time Quote from BATS)
$41.02 USD
-0.51 (-1.23%)
Updated Aug 16, 2024 12:44 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Company Summary
Foster City, CA-based Mirum Pharmaceuticals makes novel therapies for treating rare liver diseases affecting children and adults.
Mirum’s Livmarli (maralixibat), an orally administered ileal bile acid transporter (IBAT) inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also being studied for other indications. In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (PFIC). In July 2024, the European Commission approved Livmarli for the treatment of PFIC ...
Company Summary
Foster City, CA-based Mirum Pharmaceuticals makes novel therapies for treating rare liver diseases affecting children and adults.
Mirum’s Livmarli (maralixibat), an orally administered ileal bile acid transporter (IBAT) inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also being studied for other indications. In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (PFIC). In July 2024, the European Commission approved Livmarli for the treatment of PFIC in patients aged three months and older.
Meanwhile, in August 2023, Mirum acquired all the assets of Travere Therapeutics’ bile acid products. The acquisition added two other approved drugs to Mirum’s portfolio, Cholbam (cholic acid) capsules and Chenodal (chenodiol) tablets.
Cholbam is approved for treating bile acid synthesis disorders (BASD) and Zellweger spectrum disorders (ZSD). While Chenodal is not currently approved for cerebrotendinous xanthomatosis (“CTX”), it has received a medical necessity medicine status from the FDA for the same. In June 2024, the NDA for Chenodal for treating CTX patients was filed in the United States.
Mirum is developing another candidate, volixibat, an oral IBAT inhibitor, for the treatment of primary sclerosing cholangitis (“PSC”) and primary biliary cholangitis (“PBC”).
Mirum’s top line mainly comprises sales from Livmarli and recently acquired products, Cholbam and Chenodal, and license revenues.
The company reported total revenues of $186.4 million in 2023 compared with $77.1 million in 2022.
General Information
Mirum Pharmaceuticals, Inc
989 EAST HILLSDALE BOULEVARD SUITE 300
FOSTER CITY, CA 94404
Phone: 650-667-4085
Fax: NA
Web: http://www.mirumpharma.com
Email: ir@mirumpharma.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.42 |
Current Year EPS Consensus Estimate | -1.75 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 41.53 |
52 Week High | 44.94 |
52 Week Low | 23.14 |
Beta | 1.15 |
20 Day Moving Average | 649,977.00 |
Target Price Consensus | 59.09 |
4 Week | 11.13 |
12 Week | 63.06 |
YTD | 40.68 |
4 Week | 11.16 |
12 Week | 54.95 |
YTD | 21.06 |
Shares Outstanding (millions) | 47.71 |
Market Capitalization (millions) | 1,981.28 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 43.48% |
vs. Previous Quarter | 3.70% |
vs. Previous Year | 107.68% |
vs. Previous Quarter | 12.50% |
Price/Book | 8.55 |
Price/Cash Flow | NA |
Price / Sales | 7.49 |
6/30/24 | -43.47 |
3/31/24 | -56.46 |
12/31/23 | -66.24 |
6/30/24 | -16.35 |
3/31/24 | -19.61 |
12/31/23 | -23.55 |
6/30/24 | 3.28 |
3/31/24 | 3.68 |
12/31/23 | 4.45 |
6/30/24 | 3.09 |
3/31/24 | 3.47 |
12/31/23 | 4.19 |
6/30/24 | -40.34 |
3/31/24 | -52.36 |
12/31/23 | -65.53 |
6/30/24 | -40.34 |
3/31/24 | -69.67 |
12/31/23 | -86.33 |
6/30/24 | -40.64 |
3/31/24 | -70.16 |
12/31/23 | -87.15 |
6/30/24 | 4.80 |
3/31/24 | 4.98 |
12/31/23 | 5.33 |
6/30/24 | 3.39 |
3/31/24 | 3.21 |
12/31/23 | 3.15 |
6/30/24 | 1.34 |
3/31/24 | 1.31 |
12/31/23 | 1.23 |
6/30/24 | 57.30 |
3/31/24 | 56.67 |
12/31/23 | 55.20 |